Bio Pharma Dive

AUGUST 3, 2023

Sales of the company’s COVID-19 vaccine plummeted 94% year over year. But executives believe newer products can help revenue rebound.

Sales 246

Sales Vaccination Vaccine Production 246

Pharmaceutical Technology

FEBRUARY 3, 2023

Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter. in the same quarter last year.

Sales 246

Sales Vaccination Vaccine Medicine 246

Bio Pharma Dive

NOVEMBER 3, 2022

The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.

Sales 301

Sales Vaccination Vaccine Marketing 301

Bio Pharma Dive

NOVEMBER 9, 2022

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales 322

Sales Drugs Development 322

Bio Pharma Dive

JANUARY 6, 2023

The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.

Gene Therapy 311

Gene Therapy Gene Sales Development 311

Bio Pharma Dive

JULY 27, 2022

A manufacturing issue for Breyanzi, meanwhile, impacted sales. Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.

Sales 293

Sales Production Manufacturing 293

Pharmaceutical Technology

SEPTEMBER 12, 2023

The company expects the 2023 sales of its CAR-T cell therapy to be upto $570m less than projected and plans to offset this by downsizing.

Sales 130

Sales 130

Bio Pharma Dive

JANUARY 24, 2023

The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.

Sales 307

Sales Drugs 307

Bio Pharma Dive

AUGUST 1, 2023

Revenue in the second quarter declined by 53% year over year due to lower sales of Pfizer’s coronavirus vaccine and antiviral, which have been less in demand this year.

Sales 130

Sales Drugs Vaccination Vaccine 130

Bio Pharma Dive

APRIL 18, 2023

Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.

Sales 220

Sales Vaccination Vaccine Drugs 220

Bio Pharma Dive

AUGUST 10, 2023

The success of Wegovy in a landmark heart disease study has fueled higher sales projections, even though the Danish drugmaker is still struggling to maintain a big enough supply.

Sales 130

Sales Drugs 130

Pharmaceutical Technology

APRIL 19, 2023

increase in sales to $24.75bn in the first quarter (Q1) of 2023, up from $23.4bn during the corresponding quarter of 2022. In the US, sales of J&J rose by 9.7% During this period, the company’s international sales grew by 1.8% from $12.01bn to $12.23bn, and worldwide sales rose by 5.6%. from $5.15bn in Q1 2022.

Sales 130

Sales Drugs Production 130

Bio Pharma Dive

AUGUST 17, 2022

The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.

Sales 274

Sales Vaccination Vaccine Drugs 274

BioSpace

SEPTEMBER 14, 2023

After nearly seven years, the company’s rare diseases arm Alexion has reached a settlement in an investors’ lawsuit over alleged unethical sales practices for its hemoglobinuria therapy Soliris.

Sales 109

Sales 109

Bio Pharma Dive

FEBRUARY 2, 2023

Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies.

Antibody 167

Antibody Sales Drugs 167

Bio Pharma Dive

AUGUST 23, 2022

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.

Sales 284

Sales Drugs Medicine Marketing 284

Pharmaceutical Technology

JULY 21, 2023

Johnson & Johnson (J&J) has reported sales of $25.53bn in Q2 of 2023, indicating an increase of 6.3% as against $24.02bn in Q2 2022.

Sales 130

Sales 130

Pharmaceutical Technology

APRIL 28, 2023

Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.

Insulin 130

Insulin Sales FDA Approval Drugs 130

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. This would make Leqembi’s forecast sales 17 times greater than those of Aricept.

Drugs 147

Drugs Sales FDA Approval Antibody 147

Bio Pharma Dive

DECEMBER 22, 2021

Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.

FDA Approval 343

FDA Approval Drugs Sales Doctors 343

Bio Pharma Dive

MAY 4, 2022

The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

Vaccination 274

Vaccination Vaccine Sales 274

Bio Pharma Dive

OCTOBER 28, 2021

But sales could climb even higher if it works as a preventive treatment too. Executives based their projections on contracts already in place for the drug, known as molnupiravir.

Sales 313

Sales Drugs 313

Pharmaceutical Technology

JULY 19, 2023

Novartis has reported net sales of $13.62bn in Q2 of 2023, indicating a 7% rise compared to $12.78bn in the same quarter of 2022.

Sales 130

Sales 130

Bio Pharma Dive

JANUARY 31, 2023

The company expects yearly revenue from Comirnaty and Paxlovid to fall by nearly two thirds in 2023 amid lower vaccination rates and a shift to private market sales.

Vaccination 167

Vaccination Vaccine Sales Drugs 167

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022.

Vaccination 147

Vaccination Vaccine Sales Drugs 147

Bio Pharma Dive

SEPTEMBER 5, 2023

The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.

FDA Approval 326

FDA Approval Allergies Sales 326

Bio Pharma Dive

JULY 21, 2021

billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks. The pharmaceutical company expects $2.5

Sales 301

Sales Vaccination Vaccine Manufacturing 301

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. This would make Leqembi’s forecast sales 17 times greater than those of Aricept.

Drugs 130

Drugs Sales FDA Approval Antibody 130

Bio Pharma Dive

FEBRUARY 5, 2021

Sales of the antiviral drug accounted for a quarter of the biotech's product revenue in the fourth quarter, disguising hits to its business elsewhere.

Drugs 301

Drugs Sales Production 301

Bio Pharma Dive

JANUARY 25, 2023

Carvykti, which was approved a year ago for hard-to-treat multiple myeloma, generated $55 million in fourth quarter sales, the same as it earned between July and September.

Sales 167

Sales Production 167

Bio Pharma Dive

OCTOBER 18, 2021

The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines.

Drugs 284

Drugs Sales Medicine 284

Pharmaceutical Technology

OCTOBER 19, 2022

Johnson & Johnson (J&J) has reported sales of $23.79bn in the third quarter (Q3) of 2022, indicating an increase of 1.9% The reported sales in the US increased by 4.1% During this quarter, international sales saw a 0.3% decline, while worldwide sales rose by 1.9%. rise in sales to $23.3bn in Q3 2021.

Sales 130

Sales Drugs 130

Bio Pharma Dive

FEBRUARY 3, 2022

Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage.

Sales 274

Sales Doctors Doctor Drugs 274

Pharmaceutical Technology

OCTOBER 28, 2022

Merck (MSD outside North America) has reported a 14% rise in worldwide sales to $15bn in the third quarter (Q3) of 2022 as against $13.15bn in the year-ago quarter. For the quarter, pharmaceutical sales were recorded at $13bn compared to $12.7bn in Q3 2021, indicating a 13% growth. Sales from Lagevrio alone contributed to $436m.

Sales 130

Sales 130

Intouch Solutions

MAY 26, 2023

Even as some of the effects of COVID-19 have begun to wane, it’s a challenging time to be a life-sciences sales representative. Technology was supposed to bring on a new future for the sales interaction: greater insight into the customer, leading to better and more effective interactions. How can we do better?

Sales 97

Sales Life Science Marketing Development 97

Pharma Mirror

JUNE 15, 2023

Sarin Akter, a dynamic healthcare sales agent from Moulavibazar, Bangladesh, has been recently honored with iDE’s esteemed “40 Under 40” award. Her skills were honed through training from iDE, which equipped her with effective sales strategies and the ability to counsel on a range of health issues.

Sales 130

Sales Medicine Production 130

Pharma Mirror

MAY 19, 2021

Azbil Telstar announces the appointment of Rashedi Hassan as a Sales & Marketing Manager of the subsidiary of the company in Dhaka, Bangladesh. The post Rashedi Hassan takes over Sales & Marketing management of Telstar’s subsidiary in Bangladesh appeared first on Pharma Mirror Magazine. Terrassa (Barcelona).

Sales 246

Sales Marketing Life Science Engineer 246